IP Library Granted Patent US 11,492,189
Granted Patent B2
US 11,492,189 · App. 16/774,190 · Granted Nov 8, 2022

Contact lens packaging solutions containing hydrophilic polymers endcapped with a hydrophilic and a hydrophobic group

Inventors: Analuz Mark (Spencerport, NY); Ivan M. Nuñez (Penfield, NY); Vicki L. Barniak (Fairport, NY); Jennifer M. Hunt (Lake Grove, NY); Lynn Coullard (Williamson, NY); Keyla M. Cubi (Rochester, NY)
Assignee: Bausch & Lomb Incorporated
B65D81/22A45C11/005C07D263/34C08F283/124C08F290/068B65D2585/545C11D3/0047C11D3/0078C11D3/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,492,189
App. No.
16/774,190
Granted
Nov 8, 2022
Kind
B2
Abstract

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units and endcapped with a hydrophobic end group and a hydrophilic end group, wherein the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Claims (32)

1. A packaging system for the storage of an ophthalmic device comprising a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units, the one or more hydrophilic polymers or copolymers having a hydrophobic terminal end group and a hydrophilic terminal end group, wherein the aqueous packaging solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

2. The packaging system of claim 1 , wherein the ophthalmic device is a contact lens.

3. The packaging system of claim 1 , wherein the hydrophilic units are derived from at least one ethylenically unsaturated polymerizable hydrophilic monomer.

4. The packaging system of claim 3 , wherein the at least one ethylenically unsaturated polymerizable hydrophilic monomer is selected from the group consisting of an acrylamide, an acetamide, a formamide, a cyclic lactam, a (meth)acrylated alcohol, a (meth)acrylated poly(alkyleneoxy), an ethylenically unsaturated carboxylic acid, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate, a hydrophilic oxazolone monomer, and mixtures thereof.

5. The packaging system of claim 1 , wherein the hydrophilic terminal end group of the one or more hydrophilic polymers or copolymers is —OH or —CN.

6. The packaging system of claim 1 , wherein the hydrophilic terminal end group of the one or more hydrophilic polymers or copolymers is an end hydrophilic unit of the hydrophilic units.

7. The packaging system of claim 1 , wherein the hydrophilic units comprise from about 10 to about 3000 units.

8. The packaging system of claim 1 , wherein the one or more hydrophilic polymers or copolymers are derived from reversible addition fragmentation chain transfer (RAFT) polymerization.

9. The packaging system of claim 1 , wherein the hydrophobic terminal end group is selected from the group consisting of a straight or branched C 3 to C 18 alkyl group, a C 3 to C 30 cycloalkyl group, a C 6 to C 30 aryl group, a C 7 to C 30 arylalkyl group, a fluorine substituted straight or branched C 3 to C 18 alkyl group, a fluorine substituted C 3 to C 30 cycloalkyl group, a fluorine substituted C 6 to C 30 aryl groups, a fluorine substituted C 7 to C 30 arylalkyl group, a polydimethylsiloxane and an organosilicon-containing monomer.

10. The packaging system of claim 1 , wherein the one or more hydrophilic polymers or copolymers have a number average molecular weight ranging from about 1,500 Da to about 75,000 Da.

11. The packaging system of claim 1 , wherein a concentration of the one or more hydrophilic polymers or copolymers in the aqueous packaging solution ranges from about 0.01% to about 10% w/w.

12. The packaging system of claim 1 , wherein a concentration of the one or more hydrophilic polymers or copolymers in the aqueous packaging solution ranges from about 0.1 to about 5% w/w.

13. The packaging system of claim 1 , wherein the aqueous packaging solution further comprises a buffer agent, a tonicity adjusting agent, a cleaning agent, a wetting agent, a nutrient agent, a sequestering agent, a viscosity builder, a contact lens conditioning agent, an antioxidant, and mixtures thereof.

14. The packaging system of claim 1 , wherein the sealed container is heat sterilized subsequent to sealing of the container and the aqueous packaging solution does not contain an effective disinfecting amount of a disinfecting agent or a germicide compound.

15. The packaging system of claim 1 , wherein the aqueous packaging solution does not contain an effective disinfecting amount of a disinfecting agent.

16. The packaging system of claim 1 , wherein the aqueous packaging solution does not contain a germicide compound.

17. A method of preparing a packaging system comprising a storable, sterile ophthalmic device, the method comprising:

(a) providing an ophthalmic device;

(b) immersing the ophthalmic device in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units, the one or more hydrophilic polymers or copolymers having a hydrophobic terminal end group and a hydrophilic terminal end group, wherein the aqueous packaging solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9;

(c) packaging the aqueous packaging solution and the ophthalmic device in a manner preventing contamination of the ophthalmic device by microorganisms; and

(d) sterilizing the packaged solution and the ophthalmic device.

18. The method of claim 17 , wherein the ophthalmic device is a contact lens.

19. The method of claim 17 , wherein the hydrophilic units are derived from at least one ethylenically unsaturated polymerizable hydrophilic monomer selected from the group consisting of an acrylamide, an acetamide, a formamide, a cyclic lactam, a (meth)acrylated alcohol, a (meth)acrylated poly(alkyleneoxy), an ethylenically unsaturated carboxylic acid, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate, a hydrophilic oxazolone monomer, and mixtures thereof.

20. The method of claim 17 , wherein the hydrophilic terminal end group of the one or more hydrophilic polymers or copolymers is —OH and —CN.

21. The method of claim 17 , wherein the hydrophilic terminal end group of the one or more hydrophilic polymers or copolymers is an end hydrophilic unit of the hydrophilic units.

22. The method of claim 17 , wherein the hydrophilic units comprise from about 10 to about 3000 units.

23. The method of claim 17 , wherein the one or more hydrophilic polymers or copolymers are derived from reversible addition fragmentation chain transfer (RAFT) polymerization.

24. The method of claim 17 , wherein the hydrophobic terminal end group is selected from the group consisting of a straight or branched C 3 to C 18 alkyl group, a C 3 to C 30 cycloalkyl group, a C 6 to C 30 aryl group, a C 7 to C 30 arylalkyl group, a fluorine substituted straight or branched C 3 to C 18 alkyl group, a fluorine substituted C 3 to C 30 cycloalkyl group, a fluorine substituted C 6 to C 30 aryl groups, a fluorine substituted C 7 to C 30 arylalkyl group, a polydimethylsiloxane and an organosilicon-containing monomer.

25. The method of claim 17 , wherein the one or more hydrophilic polymers or copolymers have a number average molecular weight ranging from about 1,500 Da to about 75,000 Da.

26. The method of claim 17 , wherein a concentration of the one or more hydrophilic polymers or copolymers in the aqueous packaging solution ranges from about 0.01% to about 10% w/w.

27. The method of claim 17 , wherein the aqueous packaging solution further comprises a buffer agent, a tonicity adjusting agent, a cleaning agent, a wetting agent, a nutrient agent, a sequestering agent, a viscosity builder, a contact lens conditioning agent, an antioxidant, and mixtures thereof.

28. The method of claim 17 , wherein sterilizing the packaged solution and the ophthalmic device comprises heat sterilizing the packaged solution and the ophthalmic device, and the aqueous packaging solution does not contain an effective disinfecting amount of a disinfecting agent or a germicide compound.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 052589/0884) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061849/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 052589/0813) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061774/0852 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2021
From: MARK, ANALUZ; NUÑEZ, IVAN M.; BARNIAK, VICKI L.; HUNT, JENNIFER M.; COULLARD, LYNN; CUBI, KEYLA M.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 057114/0289 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded May 6, 2020
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, LTD; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 052589/0813 →
SECURITY INTEREST Recorded May 6, 2020
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, LTD; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 052589/0884 →